Molecular Oncology
Volume 2, Issue 3 , Pages 261-271 , October 2008

MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: A molecular portrait of stage 4S

  • Jean Bénard

      Affiliations

    • Molecular Interactions in Cancer CNRS-UMR 8126, IFR54, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • Medical Pathology and Biology Department, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • Corresponding Author InformationCorresponding author. Medical Pathology and Biology Department, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France. Tel.: +33 01 4211 4818.
    • ,
  • Gilda Raguénez

      Affiliations

    • Molecular Interactions in Cancer CNRS-UMR 8126, IFR54, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • Equal contributors.
    • ,
  • Audrey Kauffmann

      Affiliations

    • CNRS-FRE, 2939 IFR 54, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • Equal contributors.
    • ,
  • Alexander Valent

      Affiliations

    • CNRS-FRE, 2939 IFR 54, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • Medical Pathology and Biology Department, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • Equal contributors.
    • ,
  • Hugues Ripoche

      Affiliations

    • CNRS-FRE, 2939 IFR 54, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • ,
  • Virginie Joulin

      Affiliations

    • CNRS-FRE, 2939 IFR 54, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • ,
  • Bastien Job

      Affiliations

    • CNRS-FRE, 2939 IFR 54, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • ,
  • Gisèle Danglot

      Affiliations

    • CNRS-FRE, 2939 IFR 54, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • ,
  • Sabrina Cantais

      Affiliations

    • Molecular Interactions in Cancer CNRS-UMR 8126, IFR54, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • ,
  • Thomas Robert

      Affiliations

    • Funtional Genomics Section, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • ,
  • Marie-José Terrier-Lacombe

      Affiliations

    • Medical Pathology and Biology Department, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • ,
  • Agnès Chassevent

      Affiliations

    • Cytometry Section, Centre Paul Papin, rue Moll, Angers, France
    • ,
  • Serge Koscielny

      Affiliations

    • Biostatistiqcs & Epidemiology Department, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • ,
  • Matthias Fischer

      Affiliations

    • Department of Pediatric Oncology and Hematology, Children's Hospital, University of Cologne, Cologne, Germany
    • ,
  • Frank Berthold

      Affiliations

    • Department of Pediatric Oncology and Hematology, Children's Hospital, University of Cologne, Cologne, Germany
    • ,
  • Marc Lipinski

      Affiliations

    • Molecular Interactions in Cancer CNRS-UMR 8126, IFR54, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • ,
  • Thomas Tursz

      Affiliations

    • General Director, Institut Gustave Roussy, rue C. Desmoulins, 94805 Cedex, France
    • ,
  • Philippe Dessen

      Affiliations

    • CNRS-FRE, 2939 IFR 54, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • ,
  • Vladimir Lazar

      Affiliations

    • Funtional Genomics Section, Institut Gustave Roussy, 39, rue C. Desmoulins, Villejuif 94805 Cedex, France
    • Corresponding Author InformationCorresponding author. Functional Genomics Section, Institut Gustave Roussy, rue C. Desmoulins 94805 Cedex, France.
    • ,
  • Dominique Valteau-Couanet

      Affiliations

    • Department of Pediatric Oncology, Institut Gustave Roussy, rue C. Desmoulins, 94805 Cedex, France

Received 1 July 2008 ,Accepted 16 July 2008.

References 

  1. Ambros IM, Bénard J, Boavida M, Bown N, Caron H, Combaret V, et al Quality assessment of genetic markers used for therapy stratification. J. Clin. Oncol. 2003;21:2077–2084
  2. Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H, et al. Prognostic significance of gene expression profiles of metastatic neuroblastoma lacking MYCN amplification. J. Natl. Cancer Inst. 2006;98:1193–1201
  3. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000;25:25–29
  4. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, et al Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 2005;353:2243–2253
  5. Berasi S, Xiu M, Yee A, Paulson KE. HBP1 repression of p47phox gene: cell cycle regulation via the NADPH oxidase. Mol. Cell. Biol. 2004;24:3011–3024
  6. Bourhis J, De Vathaire F, Wilson GD, Hartmann O, Terrier-Lacombe MJ, Boccon-Gibod L, et al. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma. Cancer Res. 1991;51:33–36
  7. Bourhis J, Dominici C, McDowell H, Raschella G, Wilson G, Castello MA, et al. N-myc genomic content and DNA ploidy in stage IVS neuroblastoma. J. Clin. Oncol. 1991;9:1371–1375
  8. Brazma A, Parkinson H, Sarkans U, Shojatalab M, Vilo J, Abeygunawardena N, et al Array express, a public repository for microarray gene expression data at the EBI. Nucleic Acids Res. 2003;31:68–71
  9. Brodeur GM. Molecular basis for heterogeneity in human neuroblastomas. Eur. J. Cancer. 1995;31:505–510
  10. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer. 2003;3:203–216
  11. Chassevent A, Jourdan ML, Romain S, Descotes F, Colonna M, Martin PM, et al. S-phase fraction and DNA ploidy in 633 T1–T2 breast cancers: a standardized flow cytometric study. Clin. Cancer Res. 2001;7:909–917
  12. D'Angio G, Evans A, Koop C. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet. 1971;1:1046–1049
  13. Eleme K, Taner SB, Onfelt B, Collinson LM, Mc Cann FE, Chalupny NJ, et al. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D. J. Exp. Med. 2004;199:1005–1010
  14. Evans AE, D'Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. A Children's cancer study group. Cancer. 1971;2:374–378
  15. Filippov AK, Couve A, Pangalos M, Walsh FS, Brown DA, Moss SJ. Heteromeric assembly of GABABR1 and GABABR2 receptor subunits inhibits Ca2+ current in sympathetic neurons. J. Neurosci. 2000;20:2867–2874
  16. Fischer M, Oberthuer A, Brors B, Kahleret Y, Skowron M, Voth H, et al. Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin. Cancer Res. 2006;12:5118–5128
  17. Gasser S, Raulet DH. The DNA damage response arouses the immune system. Cancer Res. 2006;66:3959–3962
  18. Gellert M. V(D)J recombination. RAG proteins, repair factors, and regulation. Ann. Rev. Biochem. 2002;71:101–132
  19. George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, et al Hyperdiploidy plus non amplified MYCN confers a favorable prognosis in children 12 to 18months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J. Clin. Oncol. 2005;23:6466–6473
  20. Jin S, Fan F, Fan W, Zhao H, Tong T, Blanck P, et al. Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage. Oncogene. 2001;20:2683–2690
  21. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, Dessen P, et al. High expression of DNA repair pathways is associated with metastatic melanoma patients. Oncogene. 2008;27:565–573
  22. Lastowska M, Cullinane C, Variend S, Cotterill S, Bown N, O'Neill S, et al. Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J. Clin. Oncol. 2001;19:3080–3090
  23. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, et al. Evidence for an age cutoff greater than 365days for neuroblastoma risk group stratificationin the Children's Oncology Group. J. Clin. Oncol. 2005;23:6459–6465
  24. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation. N. Engl. J. Med. 1999;341:1165–1173
  25. Meddeb M, Danglot G, Chudoba I, Vénuat AM, Bénard J, Avet-Loiseau H, et al. Additional copies of a 25Mb chromosomal region originating from 17q23.1–17qter are present in 90% of high-grade neuroblastomas. Genes Chromosomes Cancer. 1996;17:156–165
  26. Monica K, Galili M, Nourse J, et al. PBX2 and PBX3, new homeobox genes with extensive homology to the human proto-oncogene PBX1. Mol. Cell. Biol. 1991;11:6149–6157
  27. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R, et al. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J. Clin. Oncol. 2006;24:5070–5078
  28. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002;62:6178–6186
  29. Rhee J, Arata A, Selleri L, Jacobs Y, Arata S, Onimaru H, et al. Pbx3 deficiency results in central hypoventilation. Am. J. Pathol. 2004;165:1343–1350
  30. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004;5:825–830
  31. Scaffidi P, Misteli T, Bianchi M. Release of chromatin protein HMGB1 by necrotic cell triggers inflammation. Nature. 2002;418:191–194
  32. Schleiermacher G, Michon J, Huon I, d'Enghien CD, Klijanienko J, Brisse H, et al Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br. J. Cancer. 2007;97:238–246
  33. Schwab M, Alitalo K, Klempnauer KH, Varmus H, Bishop JM, Gilbert F, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell line and a neuroblastoma tumor. Nature (Lond). 1983;305:245–248
  34. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol. 2003;4:472–480
  35. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of N-myc oncogene with rapid progression of neuroblastoma. N. Engl. J. Med. 1985;313:1111–1116
  36. Soumelis V, Liu Y-J. Human thymic stromal lymphopoietin: a novel epithelial cell-derived cytokine and a potential key player in the induction of allergic inflammation. Springer Semin. Immun. 2004;25:325–333
  37. Stuart LM, Henson PM, Vandivier RW. Collectins: opsonins for apoptotic cells and regulators of inflammation. Curr. Dir. Autoimmun. 2006;9:143–161
  38. Sturn A, Quackenbush J, Trajanoski Z. Genesis: Cluster analysis of microarray data. Bioinformatics. 2002;18:207–208
  39. Tomioka N, Kobayashi H, Kageyama H, Ohira M, Nakamura Y, Sasaki F, et al. Chromosomes that show segmental loss or gain in near-diploid tumors coincide with chromosomes that show whole loss or gain in near-triploid tumors: evidence suggesting the involvement of the same genes in the tumorigenesis of high- and low-risk neuroblastomas. Genes Chromosomes Cancer. 2003;36:139–150
  40. Trochet D, Bourdeaut F, Janoueix-Lerosey , Deville A, de Pontual L, Schleiermacher G, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am. J. Hum. Genet. 2004;74:761–764
  41. Valteau-Couanet D, Michon J, Boneu A, Rodary C, Perel Y, Bergeron C, et al. Results of induction chemotherapy in children older than 1year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J. Clin. Oncol. 2005;23:532–540
  42. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J. Clin. Oncol. 2005;23:2280–2299
  43. Voth H, Oberthuer A, Simon T, Kahlert Y, Berthold F, Fischer M. Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma. Mol. Cancer Res. 2007;5:1276–1284
  44. Weng L, Dai H, Zhan Y, He Y, Stepaniants SB, Bassett DE. Rosetta error model for gene expression analysis. Bioinformatics. 2006;22:1111–1121
  45. Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 1994;263:526–529

PII: S1574-7891(08)00092-6

doi: 10.1016/j.molonc.2008.07.002

Molecular Oncology
Volume 2, Issue 3 , Pages 261-271 , October 2008

Article Tools

* Image Usage & Resolution